Skip to content
Buy This GLP
← Research
Formats

Is Compounded Semaglutide Safe? What the Label Need Not Tell You

It is not FDA-approved and is not reviewed before it is dispensed. Of 33 surveyed products, 18% listed both a beyond-use date and storage conditions, and 28% listed storage conditions.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team8 min read

The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. A 2025 survey of compounding websites identified 33 semaglutide or tirzepatide products with a strength, route or formulation different from the available approved products. In that sample, 48% listed additional ingredients. Eighteen percent listed both a beyond-use date and storage conditions. In all, 28% listed storage conditions[2].

Almost every low figure on this price desk belongs to a compounded preparation. The gap against an approved product is not a discount on the same thing. It is a different regulatory route, with a different set of things known about it. That is worth setting out plainly before any figure is compared on the price check.

What "compounded" changes

A compounded incretin does not go through FDA approval[1]. A committee convened by the American College of Clinical Pharmacy reviewed these products. It reported limited data showing positive outcomes in small cohorts. It reported significant legal and safety concerns alongside them[1]. Its practical advice was to help patients get approved medication where possible. Where a patient chooses a compounded product, use a reputable pharmacy and monitor it[1].

The review of a manufacturer’s lab study explains how selected compounded and follow-on products differed from the original products in lab tests. A separate study of semaglutide sold without a prescription tested products ordered from online sellers. Each study describes the samples it tested.

Published reports of dosing errors describe a separate risk with prescriptions supplied in vials. Ask the dispensing pharmacist to check the written instructions against the vial and syringe you received.

The survey on clinician awareness examines whether patients told their clinicians they were using compounded products. Tell your care team which product and formulation you use.

The shortage ended, and the rules changed with it

The FDA declared the semaglutide and tirzepatide injection shortages resolved. Under section 503A, pharmacies generally may not regularly compound essentially copies of commercially available drugs or make them in inordinate amounts. A prescriber may document that a change makes a significant difference for an identified patient. The tirzepatide legal-status guide covers the FDA timeline and how the rules differ for outsourcing facilities[4]. Changes to compounded GLP-1 sourcing also affect what buyers can verify about the pharmacy.

A search of compounding websites in February and March 2025 identified 33 semaglutide or tirzepatide products that differed from commercially available products in strength, route or formulation[2]. Two-thirds contained semaglutide and one-third tirzepatide. Forty-eight percent added some mixture of cyanocobalamin, glycine, niacinamide, docusate or ondansetron. Of the 17 single-ingredient products, 82% were sublingual and 18% orally disintegrating tablets[2].

What the safety reporting shows

A retrospective analysis of FDA adverse-event reports for liraglutide, semaglutide and tirzepatide from 2018 to 2024 examined 81,078 reports, of which 707 involved compounded products[3]. Compounded formulations showed higher reporting odds ratios for abdominal pain, 2.84 (95% CI 2.29 to 3.49), and for cholecystitis, 3.39 (95% CI 1.61 to 6.31)[3].

The reporting odds ratio was 48.92 (95% CI 12.63 to 189.6) for preparation errors and 19.00 (95% CI 4.24 to 85.03) for contamination. The hospitalization odds ratio within the reports was 2.35 (95% CI 1.94 to 2.83)[3]. Administration and dosing errors had lower reporting odds for compounded products.

What to check before comparing prices

Check which formulation your quote covers. The ShedRx review explains how the provider bills for branded offers and compounded plans. Ask what the charge includes and which pharmacy would fill the prescription.

Use the pharmacy verification guide to confirm who dispenses the medication before you pay. Ask that pharmacy for the product-specific beyond-use date and storage instructions so you know how to handle it after delivery. Confirm the prescribed dose with your care team before using the medication.

Frequently asked

Is compounded semaglutide the same drug as the branded product?
A compounded preparation is not an FDA-approved product. Under section 503A, pharmacies generally may not regularly compound essentially copies of commercially available drugs or make them in inordinate amounts. A prescriber may document that a change produces a significant difference for an identified patient.
Are the added ingredients a benefit?
The published survey found little justification for adding nutrients or docusate sodium to these combinations. FDA says an injectable semaglutide and vitamin B12 combination may still be considered essentially a copy under section 503A, depending on the comparable products and prescriber documentation.
What can a buyer actually check?
Check whether the pharmacy is named, the milligram dose is specified, and the beyond-use date and storage conditions are provided. Of 33 surveyed products, 18% listed both a beyond-use date and storage conditions, and 28% listed storage conditions.

Sources

  1. [1] Courtney LA, et al. (2025). Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy Diabetes & Metabolic Syndrome. PMID 41176849
  2. [2] Belcourt J, et al. (2026). Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown Annals of Pharmacotherapy. PMID 41689811
  3. [3] McCall KL, et al. (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system Expert Opinion on Drug Safety. PMID 40285721
  4. [4] U.S. Food and Drug Administration (2026). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize FDA. Source

More in Formats